The Moschitto Research Group, which started in September of 2019 at Rutgers University, aims to provide additional methods for the treatment of various diseases through the development of new covalent therapeutics that combines synthetic organic chemistry, and medicinal chemistry.    Over the past decade, there has been a resurgence in the use of covalent inhibitors. The formation of a covalent bond results in complete and prolonged target inhibition leading to a lower dosage needed to obtain a similar effect to that of a reversible inhibitor.  Given the lessened need for noncovalent interactions, covalent inhibitors can also bind effectively in shallow binding sites, thus expanding the scope of druggable targets. Overall, covalent inhibitors do not require continual administration, reducing the necessity of hospital visits, the cost of the treatment, and potential side effects.    Our major efforts include developing additional methods to synthesize novel carbon-sulfur bonds for use in the synthesis of sulfonyl fluorides.  We apply our sulfonyl fluoride small molecules to target promising protein targets implicated in various cancers.